证券代码： 000919 证券简称：金陵药业 公告编号：2023-078 金陵药业股份有限公司 关于公司及子公司使用闲置资金购买理财产品进展的公告 二、风险揭示 公司及子公司购买的理财产品全部为低风险理财产品，虽风险较 低，但与银行存款相比，存在一定风险，其可能面临的主要风险如下： 1、政策风险：理财产品在实际运作过程中，如遇到国家宏观政 策和相关法律法规发生变化，影响理财产品的发行、投资和兑付等， 可能影响理财产品的到期收益。 2、市场风险：理财产品在实际运作过程中，由于市场的变化会 造成理财产品投资的资产价格发生波动，从而影响理财产品的收益， 公司面临收益遭受损失的风险。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 2023 年 3 月 22 日，金陵药业股份有限公司（以下简称"金陵药 业"或"公司"）第八届董事会第二十八次会议审议通过了《关于公 司及子公司使用闲置自有资金进行委托理财的议案》。同意公司及子 公司使用不超过 4 亿元（余额）闲置自有资金购买银行或金融机构发 行的低风险理财产品，在上述额度内资金可循环投资，滚动使用。使 用期限自公司本次董 ...

金陵药业股份有限公司规章制度管理制度 （经第九届董事会第二次会议审议通过） 第一章 总则 第一条 为规范金陵药业股份有限公司（以下简称"公司"）规章制度 管理工作，加强规章制度的管理，确保规章制度的合法性、系统性、科学 性和可执行性，根据《中华人民共和国公司法》《金陵药业股份有限公司 章程》（以下简称"章程"）及有关规定，制定本制度。 第二条 公司规章制度的制定计划、起草、审核、批准、备案、发布、 解释、修订和废止等管理工作，适用本制度。各分公司、全资和控股企业 （以下简称"所属企业"）参照本制度执行。 第三条 公司规章制度管理遵循以下原则： （一）合法性：规章制度的内容应当符合法律法规规定，其制定、修 改和废止等应符合本制度规定和要求。 （二）系统性：公司应有规划、按计划、持续完善规章制度体系，制 度间的规定应有效衔接、不冲突。 （三）科学性：规章制度应符合公司发展实际，与公司发展战略、业 务活动及管理目标协调一致。 （四）可执行性：规章制度表述应当准确、规范、简洁、一致，定位 准确、层级分明、职责清晰、权责明确、结构合理，具有可执行性。 第二章 规章制度的分类与管理原则 2、规则是指根据公司章程制定的，规 ...

证券代码：000919 证券简称：金陵药业 公告编号：2023-075 金陵药业股份有限公司 第九届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、金陵药业股份有限公司（以下简称"公司"）第九届董事会第 二次会议通知于 2023 年 8 月 8 日以专人送达、邮寄、电子邮件等方 式发出。 2、本次会议于 2023 年 8 月 18 日以通讯会议的方式召开。 3、会议应参与表决董事 9 名，实际参与表决董事 9 名，收到有 效表决票 9 张。 4、本次董事会会议的召开符合有关法律、行政法规、部门规章、 规范性文件和《公司章程》的规定。 二、董事会会议审议情况 1、审议通过《金陵药业股份有限公司 2023 年半年度报告及报告 摘要》。 表决结果：9 票同意，0 票反对，0 票弃权 具体内容详见 2023 年 8 月 19 日巨潮资讯网刊登的《公司 2023 三、备查文件 1、经与会董事签字并加盖董事会印章的董事会决议； 2、深交所要求的其他文件。 年半年度报告全文》，以及 2023 年 8 月 19 日《中国证 ...

金陵药业股份有限公司独立董事 2、报告期内，公司不存在大股东及其他关联方占用上市公司资金 的情况。 3、报告期内，公司严格控制了对外担保风险，报告期内公司无对 外担保事项。 （此页无正文，系金陵药业股份有限公司独立董事关于公司第九 届董事会第二次会议审议的有关议案及相关事项的独立董事签字页） 关于公司第九届董事会第二次会议审议的有关议案 及相关事项的独立意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《深圳证券交易所 股票上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号—— 主板上市公司规范运作》、《上市公司独立董事规则》和《公司章程》、 公司《独立董事工作制度》等有关规定，我们本着公平、公正、客观 的原则，作为金陵药业股份有限公司的独立董事，对公司 2023 年 8 月 18 日召开的第九届董事会第二次会议（以下简称"本次会议"）审 议的有关议案及相关事项发表如下独立意见： 对公司当期关联方资金占用和对外担保情况的专项说明和独立 意见 1、报告期内，公司因与关联方在采购和销售商品方面存在日常关 联交易，发生了正常的经营性资金往来， ...

| | 浙江金陵浙 磐药材开发 | 子公司 | 其他应收款 | 39.75 | - | - | 39.75 | - | 往来 | 经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 有限公司 | | | | | | | | | | | | 云南金陵植 物药业股份 有限公司 | 子公司 | 其他应收款 | 30.83 | - | - | 30.83 | - | 往来 | 经营性往来 | | | 池州东升药 | 子公司 | 其他应收款 | 9.75 | - | - | 9.75 | - | 往来 | 经营性往来 | | | 业有限公司 | | | | | | | | | | | | 小计 | | | 3,070.82 | 4,172.31 | - | 6,048.73 | 1,194.40 | | | | 其他关联方及其 附属企业 | 南京益同药 业有限责任 | 联营企业 | 应收账款 | 6,538.08 | 12,000.69 | | 10,094.87 | 8,443.90 | 销售 | 经营性往来 ...

证券代码：000919 证券简称：金陵药业 金陵药业股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------------|--------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------| | | | 编号：2023-002 | | | √特定对象调研 | □分析师会议 | | 投资者关系 | □媒体采访 □业绩说明会 | | | 活动类别 | □新闻发布会 □路演活动 | | | | □现场参观 □电话会议 | | | | □其他： （请文字说明其他活动内容） | | | | （排名不分先后） | | | | 兴业证券：徐尚微、姚晟瑜，中信保诚：陈爽， | | | 参与单位名称 | | 浦银安盛：徐博，兴银理财：卢新平，华安资产：房晓， ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥708,534,720.18, representing a 2.24% increase compared to ¥693,016,544.54 in the same period last year[5] - Net profit attributable to shareholders was ¥43,585,110.26, reflecting an 11.07% increase from ¥39,240,141.55 year-on-year[5] - Basic and diluted earnings per share increased by 12.48% to ¥0.0865 from ¥0.0769 in the same period last year[5] - Total operating revenue for Q1 2023 was CNY 708,534,720.18, an increase of 2.2% compared to CNY 693,016,544.54 in the same period last year[18] - Net profit for Q1 2023 reached CNY 49,325,374.22, representing a 10.5% increase from CNY 44,443,693.56 in Q1 2022[20] - The total comprehensive income attributable to minority shareholders for Q1 2023 was CNY 5,740,263.96, compared to CNY 5,203,552.01 in Q1 2022, representing an increase of approximately 10.3%[21] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.0865, up from CNY 0.0769 in Q1 2022, reflecting a growth of about 7.4%[21] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, reaching -¥25,354,145.88, a 65.01% increase compared to -¥72,458,661.05 in the previous year[5] - Cash inflow from operating activities totaled CNY 675,761,687.56 in Q1 2023, compared to CNY 626,808,280.41 in Q1 2022, indicating an increase of approximately 7.8%[21] - Cash outflow from operating activities was CNY 701,115,833.44 in Q1 2023, slightly up from CNY 699,266,941.46 in Q1 2022, resulting in a net cash flow from operating activities of -CNY 25,354,145.88, an improvement from -CNY 72,458,661.05 in Q1 2022[21] - Investment activities generated a net cash flow of -CNY 209,375,029.15 in Q1 2023, compared to -CNY 460,424,469.27 in Q1 2022, showing a significant reduction in cash outflow[22] - Cash inflow from financing activities was CNY 3,681,573.36 in Q1 2023, down from CNY 23,616,000.00 in Q1 2022, indicating a decrease of approximately 84.4%[22] - The net increase in cash and cash equivalents for Q1 2023 was -CNY 231,087,932.62, compared to -CNY 524,349,156.37 in Q1 2022, reflecting an improvement in cash management[22] - The ending balance of cash and cash equivalents as of the end of Q1 2023 was CNY 1,243,795,533.31, compared to CNY 957,243,394.73 at the end of Q1 2022, representing an increase of approximately 30%[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,521,604,404.57, a slight decrease of 0.48% from ¥4,543,352,930.71 at the end of the previous year[5] - The total current assets decreased slightly to CNY 2,616,014,317.82 from CNY 2,633,145,031.76, reflecting a decline of 0.65%[15] - The total liabilities decreased to CNY 845,385,207.46 from CNY 916,299,000.51, indicating a reduction of approximately 7.7%[17] - The equity attributable to shareholders of the parent company increased to CNY 3,037,602,730.81 from CNY 2,994,177,727.86, reflecting a growth of 1.4%[17] Research and Development - The company reported a 49.55% increase in R&D expenses, totaling ¥14,231,193.78 compared to ¥9,516,114.99 in the previous year[9] - The company's R&D expenses increased to CNY 14,231,193.78, up from CNY 9,516,114.99, marking a 49.5% rise year-over-year[18] - The company has plans for market expansion and new product development, as indicated by ongoing investments in research and development[14] - The company’s financial performance indicates a stable outlook with a focus on cost management and strategic investments in R&D[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 50,056, with the largest shareholder holding 44.60% of the shares[10] Other Significant Events - Government subsidies recognized in the current period amounted to ¥8,458,972.91, a 407.63% increase from ¥1,666,372.01 in the previous year[9] - The company is in the process of issuing A-shares to specific investors, which may involve related transactions[14] - The company has received compensation for part of the demolition from Zhejiang Tianfeng Pharmaceutical Factory, which may impact future cash flows[13] - The company is adjusting its management structure, including changes to the board secretary, which may influence operational efficiency[14] - The company did not conduct an audit for the Q1 2023 report[23]

答：投资者，您好。关于福州市投资管理有限公司减持公司股份的情 况，请参阅《中国证券报》《证券时报》《上海证券报》及巨潮资讯网 刊登的《关于特定股东减持股份预披露公告》《特定股东减持股份计划 时间过半暨减持进展情况的公告》。谢谢！ 证券代码：000919 证券简称：金陵药业 金陵药业股份有限公司 金陵药业 2022 年度业绩说明会 投资者活动记录表 编号：2023-001 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □电话会议 □其他： （请文字说明其他活动内容） 参与单位名称 及人员姓名 金陵药业2022年度业绩说明会采用网络远程方式进行，面向全体投资 者 时间 2023 年 4 月 7 日 15:00-16:30 地点 深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云访谈"栏目 公司接待人员 姓名 主持人：金陵药业 董事长：梁玉堂 副董事长、总裁：陈亚军 董秘：陈海 副总裁、总会计师：汪洋 独立董事：沈永建 投资者关系活动 主要内容介绍 1.陈总裁好，我想问下公司 2022 年控股的池州东升药业进展怎样？ ...

易"平台（http://irm.cninfo.com.cn/）或下方二维码留言提问， 公司将对投资者普遍关注的问题进行回答。欢迎广大投资者积极参与。 金陵药业股份有限公司 关于召开 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 金陵药业股份有限公司（以下简称"公司"）已于 2023 年 3 月 24 日在巨潮资讯网（www.cninfo.com.cn）披露了《公司 2022 年年 度报告》（公告编号：2023-031）。 为使广大投资者进一步了解公司 2022 年年度报告的相关内容， 公司定于 2023 年 4 月 7 日（星期五）下午 3:00-4:30 举行 2022 年度 网上业绩说明会，本次年度业绩说明会将通过深圳证券交易所提供的 "互动易"平台举行，投资者可登录"互动易"平台 （http://irm.cninfo.com.cn）,进入"云访谈"栏目参与本次年度 业绩说明会。 出席本次年度业绩说明会的人员有：董事长梁玉堂先生，副董事 长、总裁陈亚军先生，独立董事沈永建先生，副总裁、总会计师汪洋 先生和董事会秘书陈海 ...

Financial Performance - The company's operating revenue for 2022 was approximately ¥2.67 billion, a decrease of 4.91% compared to ¥2.81 billion in 2021[24]. - The net profit attributable to shareholders for 2022 was approximately ¥105.28 million, down 12.72% from ¥120.63 million in 2021[24]. - The net profit after deducting non-recurring gains and losses was approximately ¥63.72 million, a decline of 11.70% from ¥72.16 million in 2021[24]. - The cash flow from operating activities for 2022 was approximately ¥260.59 million, a decrease of 10.76% compared to ¥292.03 million in 2021[24]. - The total assets at the end of 2022 were approximately ¥4.54 billion, an increase of 2.15% from ¥4.45 billion at the end of 2021[24]. - The net assets attributable to shareholders at the end of 2022 were approximately ¥2.99 billion, up 2.27% from ¥2.93 billion at the end of 2021[24]. - The basic earnings per share for 2022 were ¥0.2089, down 12.70% from ¥0.2393 in 2021[24]. - The weighted average return on equity for 2022 was 3.54%, a decrease of 0.62% from 4.16% in 2021[24]. - The company achieved total operating revenue of 2,670.968 million yuan and a net profit attributable to shareholders of 1,052.819 million yuan in 2022[48]. - The company reported a gross margin of 34.37% for pharmaceutical production and sales, which is an increase of 1.47% compared to the previous year[59]. - The company reported a total revenue of 1,273,108,500 CNY for its subsidiary Suqian Hospital, with a net profit of 32,964,877 CNY[88]. - The company reported a total revenue of 2.8836 billion CNY for the year 2022, reflecting a significant growth compared to the previous year[106]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2022, representing a year-over-year increase of 10%[114]. Dividend Distribution - The company plans to distribute a cash dividend of 1.0 RMB per 10 shares (including tax) based on a total of 511,136,000 shares[3]. - The cash dividend distribution plan for the reporting period included a cash dividend of 1.0 yuan per 10 shares, totaling 51,113,600 yuan, which represents 100% of the total profit distribution[138]. - The company has maintained a complete decision-making process for its cash dividend policy, ensuring the protection of minority shareholders' rights[138]. - The company plans to distribute a cash dividend of CNY 1.00 per 10 shares, totaling CNY 51,113,600.00, with the remaining undistributed profit of CNY 811,804,540.03 carried forward to future years[140]. Business Operations and Strategy - The company has expanded its business scope to include medical services and health care services following acquisitions in 2003 and 2018[22]. - The company’s business model remains unchanged compared to the previous year, focusing on pharmaceutical manufacturing and healthcare services[44]. - The company is focusing on expanding its market presence through diversified product sales, including medical devices and agricultural products[49]. - The company is committed to enhancing its operational efficiency by dynamically adjusting production plans and improving resource allocation[49]. - The company is focusing on expanding its market presence and enhancing its product offerings through new technology development and strategic acquisitions[110]. - The company is strategically positioned to leverage its experienced management team to drive future growth and operational efficiency[110]. - The company plans to pursue strategic acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for potential mergers in 2023[114]. Research and Development - The company invested CNY 74.17 million in R&D during the reporting period, representing a year-on-year increase of 30%[52]. - Research and development expenses increased by 30.09% to CNY 74,170,064.98, driven by new projects[67][68]. - The company has a total of 13 employees with doctoral degrees and 388 with master's degrees, reflecting a strong educational background among its workforce[134]. - The company has established a dedicated committee for innovation development, aiming to enhance its competitive edge in the market[112]. - The company’s new product "Cicada Slough Cough Granules" has completed clinical research and is awaiting approval[54]. - The company has been actively involved in various technology projects, including the successful application for the Jiangsu Province Science and Technology Achievement Transformation Project[52]. Market and Competition - The company acknowledges risks related to industry policy changes, market competition, and raw material price fluctuations[3]. - The company aims to enhance its product quality and R&D capabilities to maintain competitive advantages in a highly concentrated market[91]. - The company is focusing on expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[114]. Governance and Compliance - The company has implemented a governance structure that complies with relevant laws and regulations, enhancing its governance level[96]. - The board of directors operates independently, with specialized committees focusing on strategy, audit, nomination, and remuneration[97]. - The company emphasizes transparent information disclosure, utilizing multiple media outlets to ensure all investors have equal access to information[98]. - The company has established an independent financial department with a standardized accounting system and independent bank accounts, ensuring compliance with tax regulations[100]. - The company has implemented a comprehensive internal control system to ensure compliance with relevant laws and regulations[148]. - The internal control audit report issued on March 24, 2023, received a standard unqualified opinion, confirming the effectiveness of financial reporting controls[153]. Environmental Management - The company has implemented self-monitoring plans in accordance with relevant regulations, ensuring stable compliance with pollutant discharge[164]. - The company invested CNY 9.2799 million in environmental protection efforts[168]. - The company maintained compliance with environmental regulations, adhering to standards set by various environmental protection laws[156]. - Jinling Pharmaceutical's environmental management practices include strict adherence to wastewater and air quality standards, demonstrating commitment to sustainability[156]. Employee Management - The total number of employees at the end of the reporting period was 4,880, with 3,475 in technical roles, 458 in production, and 95 in sales[134]. - The company conducted 481 training programs in 2022, achieving an overall training plan completion rate of over 85% and spending over 3 million yuan on education expenses[136]. - The company has implemented a flexible benefits plan to meet diverse employee welfare needs and enhance employee satisfaction[135]. - The company has established a dual-driven talent development system focusing on theoretical learning and practical training[135]. Legal and Regulatory Matters - The company has not reported any significant changes in its business, products, or services during the reporting period[66]. - There were no significant lawsuits or arbitration matters during the reporting period[188]. - The company reported no violations of external guarantees during the reporting period[181]. - The company did not experience any bankruptcy reorganization during the reporting period[187].